US EditionRecce secures Chinese patent for anti-infective drug candidates - Manufacturers' Monthly
Summary by Manufacturers' Monthly
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Recce secures Chinese patent for anti-infective drug candidates - Manufacturers' Monthly
Image: RecceRecce Pharmaceuticals Ltd has expanded its global intellectual property portfolio, with the company announcing that it has received a Notice of Acceptance in China for a patent for its synthetic anti-infective candidates RECCE® 327 and RECCE® 529. The patent is valid through to 2041 and marks the fifth granted under Patent Family 4, with prior approvals in Australia, Canada, Israel and Japan. The Chinese pharmaceutical market is the …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
